Synonyms: 6-Chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide hydrochloride; N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide hydrochloride; N-1-Azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazine-8-carboxamide monohydrochloride; Y 25130; Y-25130; Y25130
Molecular Formula: C17H20ClN3O3 · HCl
Molecular Weight: 386.27
Linear Structural Formula: C17H20ClN3O3 · HCl
MDL Number: MFCD00209913
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: Azasetron (Y-25130) is an orally active, potent and selective 5-HT3 receptor antagonist (binding Ki = 0.33 nM against [3H]granisetron/rat small intestine, 2.9 nM against [3H]quipazine/rat cortex; little or no affinity toward H1,d5-HT1A/2, Dopamine D1/2, alpha1/alpha2 adrenoceptor, muscarinic receptors) with in vivo antiemetic efficacy (0.1-0.3 mg/kg i.v. & 0.1-1 mg/kg p.o.; dogs, ferrets). Y-25130 inhibits 5-HT-induced bradycardia in anesthetized rats (ED50 = 820 ng/kg i.v.), while concurrent intrahippocampal infusion (1.0 mug/side) prevents memory function impairment caused by muscarinic acetylcholine receptor antagonist scopolamine (3.2 mug/side), but not NMDA receptor antagonist CPP (32 ng/side).